Kymera prices $275M public offering of common stock and pre-funded warrants

Kymera Therapeutics, Inc.

Priced public offering of 2.25M shares at $25.25 and 8.64M pre-funded warrants at $25.2499; gross proceeds ~$275M.
Underwriters' option for additional 1.63M shares exercised in full; net proceeds estimated ~$301.1M.
Preliminary cash, cash equivalents and marketable securities of ~$436M as of Dec 31, 2023, excluding $15M Sanofi milestone.
Cash runway expected into first half of 2027 based on current plans and offering proceeds.
Offering led by Morgan Stanley, J.P. Morgan, and TD Cowen; close expected Jan 9, 2024.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.